Executive summary
US Drug Patent 11,530,408 claims broad iRNA duplexes defined by: (i) a sense/antisense sequence architecture with a blunt end on one side and an overhang on the other, (ii) a constrained window (within the first 3–6 positions from either duplex end) where the identity of “first” and “second” monomers is selected so that pairing stability to the target differs from pairing between the iRNA strands, and (iii) extensive dependent claim fallbacks covering specific base pair types, mismatches, and sugar/base modifications. The scope is anchored by sequence indexing (P−5…P−1 and P5…P1) and by functional “stability difference” language. This is a strong claim posture for covering many design variants of duplex formation and terminal end symmetry breaks, but it will be highly sensitive in litigation to how “stability” is measured or construed and to how strictly the claimed terminal/positional constraints are met.
What is US Patent 11,530,408 and what does it claim about iRNA duplex structure?
High-level claim gist: The independent claim is directed to an interfering RNA (iRNA) duplex where (1) duplex ends are asymmetrical (blunt vs overhang), (2) the duplex contains defined sense/antisense sequences, and (3) there is a monomer/position design rule in a 3–6 nucleotide window from a duplex end to create differential duplex-stability behavior versus stability of pairing to a target (sense-to-target or antisense-to-target pairing). The claim is implemented through a structured sequence notation with positional indices P−5…P−1 and P5…P1 (and an optional set of additional base-pairs).
Claim 1 architecture (core elements)
1) Duplex type and end morphology
- “iRNA duplex has a blunt end at one end of the iRNA duplex and an overhang at the other end.”
2) Positional window for designed monomer selection
- “first monomer in a first sequence and a second monomer in a second sequence within the first 3, 4, 5, or 6 positions from either the 3′ end or the 5′ end”
3) Stability-difference functional requirement
- “first and second monomers are selected such that the stability of the pairing of the monomers contributing to forming a duplex between the first and second sequences differs from the stability of the pairing between the first sequence and a target sequence or between the second sequence and a target sequence.”
4) Sequence representation that anchors “where” the design sits
The claim recites a formal depiction:
- Sense strand corresponds to “second sequence” (S)
- Antisense strand corresponds to “first sequence” (AS)
- Optional overhangs: R1 (sense 5′ overhang), R2 (sense 3′ overhang), R3 (antisense 3′ overhang), R4 (antisense 5′ overhang)
- A positional pairing series Px, where x = −5 to 5: “Px is a pairing of sense Nx and antisense Nx where x is −5 to 5.”
This is the claim’s structural anchor. Most design-around risk centers on whether an accused duplex falls within the defined index window (and whether it meets the end asymmetry limitation).
Claim 6: an important independent re-statement that tightens one positional constraint
Claim 6 repeats essentially the same platform but adds a specific condition:
- “subunit at P−1 of the 5′-end of the antisense strand is A or a modified base which pairs with T or U (or the complementary “modified base pairs with A”)”
- “and wherein the subunits at P−1 are the first monomer and second monomer, respectively.”
This matters because it converts an otherwise general monomer-selection window into a fixed base identity requirement at P−1 (antisense 5′ proximal position).
Where does the claim scope concentrate: P−5 to P−1 vs P5 to P1 and end overhangs?
Featured-snippet answer: The claim is built around positional base-pair blocks at P−5…P−1 (and also allows defined constraints at P5…P1 via dependents), plus strict duplex end morphology: blunt on one end and overhang on the other.
Positional block P−5 through P−1 (antisense 5′-proximal region)
Dependent claims repeatedly target:
- “one or more pairs in P−5 through P−1 are independently A:U, G:U, I:C, or mismatched pairs.” (Claim 2)
- “one or more pairs in P−4 through P−1 are G:U pairs.” (Claim 3)
- “one or more pairs in P−5 through P−1 are A:U pairs.” (Claim 4)
- “one or more pairs in P−3 through P−1 are A:U pairs.” (Claim 5)
- Claim 9 combines P−5…P−1 options with P5…P1 options.
Interpretation for product-risk mapping: Many siRNA/iRNA designs tolerate U/G wobble at terminal positions. These dependents indicate the patentee expects infringement arguments to focus on non-Watson-Crick terminal pairing patterns in the 5′-side window of the antisense strand (as indexed by P−).
Positional block P5 through P1 (sense/antisense terminal-proximal region on the opposite end)
Dependent claim 7 covers:
- “one or more pairs in P5 through P1 are independently G:C, A:T, A:U, 2-amino-A:U, 2-thio U or 5 Me-thio-U:A, G-clamp:G, guanadinium-G-clamp:G; pseudo uridine:A”
- and “or a pair in which one or both subunits has a sugar modification.”
Interpretation: The patentee has drafted an intentionally broad catalog of base-pair chemistries and sugar substitutions that are common in nuclease-resistant, immunomodulatory, or binding-affinity tuning strategies.
End morphology constraints (blunt/overhang combinations)
- Claim 14: “blunt end at the 5′-end of the antisense strand and a two-nucleotide overhang at the 3′-end of the antisense strand.”
- Claim 20: same blunt/2-nt overhang combination.
Product-risk mapping: If an accused duplex is designed with the canonical siRNA end pattern (often 19–21 mers with a 2-nt 3′ overhang), these dependents can become central to claim construction and infringement analysis, especially if the independent claim is argued as satisfied by end asymmetry alone and the dependents are used to narrow to a “more standard” commercial design.
How does the “stability differs” language shape infringement and validity risk?
The independent claim requires that monomer identities in the terminal window are selected such that pairing stability differs between:
- inter-molecular duplex formation pairing (first sequence vs second sequence), and
- intra-molecular pairing to target (first sequence vs target or second sequence vs target).
What this does to claim scope
- It is a functional limitation. Two duplexes with identical sequences could avoid literal infringement if a court finds their “stability” does not “differ” in the claimed sense, or if stability differences are not tied to the claimed monomers.
- It also potentially expands scope beyond exact base identity where the “monomer selection” is what drives the stability behavior.
Litigation focal points implied by the claim text
- How “stability” is measured (thermodynamic models, melting temperature, base-pair stacking free energy, etc.) becomes a key dispute.
- Whether the “target sequence” is defined with sufficient specificity in the patent record to avoid indefiniteness arguments (not assessed here because the provided excerpt does not include the specification or definitions).
What specific nucleotide pairing and modifications are covered by the dependent claims?
Base pair types explicitly enumerated
From the claim set provided:
P−5…P−1 (antisense 5′-proximal)
- A:U (Claim 2, 4)
- G:U (Claim 2, 3)
- I:C (Claim 2)
- “mismatched pairs” (Claim 2)
mismatch definition refinement
- Claim 10: “pairing… has a decreased stability”
- Claim 11: mismatch
- Claim 12: mismatch refers to “no pairing or a non-canonical Watson-Crick pairing”
- Claim 13: mismatch includes “non-canonical Watson-Crick pairing selected from”:
- U:U
- G:G
- G:Atrans
- G:Acis
- G:U
P5…P1 (opposite end window options)
- G:C, A:T, A:U
- 2-amino-A:U
- 2-thio U or 5 Me-thio-U:A
- G-clamp:G
- guanadinium-G-clamp:G
- pseudo uridine:A
- sugar-modified pairs (“one or both subunits has a sugar modification”) (Claim 7)
Biologically common relevance for design
These dependents align with common siRNA chemistry:
- wobble base pairing to tune strand selection
- inosine base pairing
- thio/thioether and methylthio modifications
- base clamps and pseudo-uridine type substitutions
- sugar modifications to improve half-life and reduce immune activation
What length constraints and positional constraints are claimed?
Strand lengths
- Claim 15: each strand 15–30 nucleotides
- Claim 16: each strand 19–25 nucleotides
- Claim 17: one strand 21 nt and the other 23 nt
This is commercially significant because many siRNA products use 19–21 nt duplexes with 2-nt 3′ overhangs. Claim 17 tracks a typical design symmetry break (21/23 with overhang).
Positional numbering constraints
- The claim uses “within the first 3, 4, 5, or 6 positions from either the 3′ end or the 5′ end” (Claim 1)
- plus a specific “P−1 of the 5′-end of the antisense strand” condition in Claim 6.
These constraints reduce the feasible design-around space for parties who otherwise try to vary chemistry outside a small terminal window.
What is the practical claim coverage map for an accused iRNA duplex product?
Literal coverage is most likely where the accused duplex satisfies simultaneously:
- blunt vs overhang end asymmetry
- terminal window placement of designed monomers (3–6 positions from an end)
- a differential stability relationship to a target pairing state
- and, depending on how infringement is pleaded, additional narrowing limitations such as:
- A:U / G:U / I:C / mismatch presence in P−5…P−1
- optional A:U requirement at P−1 (Claim 6)
- specific mismatch types (U:U, G:G, etc.) if the patentee uses Claim 13
- canonical blunt/2-nt antisense 3′ overhang structure (Claim 14/20)
- base/sugar modifications on the opposite side (Claim 7)
Because the dependents enumerate many base chemistries, the claim set functions like a menu: accused products can be matched to one or more dependent claims even if the independent claim is disputed on the stability-difference proof element.
How could a generic or competitor design around this US patent claim set?
Design-around levers implied by the claim language:
- Change end morphology so it is not “blunt at one end and overhang at the other” or specifically avoid the two-nucleotide antisense 3′ overhang pattern tied to Claim 14/20.
- Move the designed monomer-selection region outside the first 3–6 positions from an end.
- Remove the specific positional requirement at P−1 of the antisense 5′ end (Claim 6) if the patentee asserts that dependent.
- Avoid the enumerated mismatch types if infringement is pleaded under Claim 13.
- Avoid the listed base pair chemistries and sugar modifications if infringement is pleaded under Claim 7 for P5…P1.
- Challenge the functional element: do not select monomers to produce a “stability differs” behavior as characterized relative to target pairing.
The key point for business decisioning: this patent is written so that even if you adjust base chemistry, you can still land in a dependent claim unless you also change the positional window, the end morphology, or the stability-to-target relationship.
What does this mean for licensing, freedom-to-operate, and litigation risk?
Risk profile
- The claim language is broad on strand length (15–30; and narrower 19–25), broad on end asymmetry, and broad on allowable chemistry through enumerated dependent categories.
- The main litigation friction is the functional “stability differs” feature, which is often a fact-intensive claim construction and evidence question.
Evidence pressure
- In enforcement, the patentee will likely use experimental thermodynamics or computational models to show that the claimed monomer selection changes inter-strand stability differently than target pairing stability.
- In defense, parties will attempt to show that any apparent stability differences do not satisfy the claimed “differs from the stability” relationship in the manner required.
Key Takeaways
- US 11,530,408 claims asymmetric iRNA duplex ends and a terminal-window monomer selection rule that creates a differential stability relationship between duplex formation and target pairing.
- Scope is anchored by a structured sequence notation with positional blocks P−5…P−1 and P5…P1, plus specific end-pattern dependents.
- Dependent claims enumerate many common siRNA chemistry options: A:U, G:U, I:C, multiple explicit mismatch types (U:U, G:G, G:Atrans, G:Acis, G:U), and modifications including thio/methylthio U, G-clamp, guanidinium-G-clamp, pseudo-uridine, and sugar-modified pairs.
- The highest-value design-around levers are end morphology, where the monomer selection occurs, and the P−1 antisense 5′ base condition in Claim 6, plus contesting the stability-difference functional limitation.
FAQs
-
What duplex end pattern is explicitly required by US 11,530,408 dependents?
The dependents specify a blunt end and, in Claim 14/20, a two-nucleotide overhang at the 3′ end of the antisense strand.
-
Which mismatch types are expressly listed in the claim set?
U:U, G:G, G:Atrans, G:Acis, and G:U.
-
Does the patent cover iRNA lengths outside 19–25 nucleotides?
Yes. Claim 15 covers 15–30 nt per strand, with narrower dependents at 19–25 nt and a specific 21/23 nt arrangement (Claim 17).
-
What base-pair chemistries are listed for the P5 through P1 region?
G:C, A:T, A:U, multiple thio/amino variants (2-amino-A:U, 2-thio U, 5 Me-thio-U:A), and noncanonical options like G-clamp, guanidinium-G-clamp, pseudo uridine:A, plus sugar-modified pairs.
-
What is the most litigation-sensitive element beyond sequence and chemistry?
The functional “stability differs” relationship between duplex pairing stability and target pairing stability.
References (APA)
- United States Patent 11,530,408. (Issued as stated in prompt).
